Search

Your search keyword '"LA CORTE, Renato"' showing total 115 results
Start Over Author "LA CORTE, Renato"
115 results on '"LA CORTE, Renato"'

1. Serum Jo-1 Autoantibody and Isolated Arthritis in the Antisynthetase Syndrome: Review of the Literature and Report of the Experience of AENEAS Collaborative Group

Author

Cavagna, Lorenzo, Nuño, Laura, Scirè, Carlo Alberto, Govoni, Marcello, Longo, Francisco Javier Lopez, Franceschini, Franco, Neri, Rossella, Castañeda, Santos, Sifuentes Giraldo, Walter Alberto, Caporali, Roberto, Iannone, Florenzo, Fusaro, Enrico, Paolazzi, Giuseppe, Pellerito, Raffaele, Schwarting, Andreas, Saketkoo, Lesley Ann, Ortego-Centeno, Norberto, Quartuccio, Luca, Bartoloni, Elena, Specker, Christof, Pina Murcia, Trinitario, La Corte, Renato, Furini, Federica, Foschi, Valentina, Bachiller Corral, Javier, Airò, Paolo, Cavazzana, Ilaria, Martínez-Barrio, Julia, Hinojosa, Michelle, Giannini, Margherita, Barsotti, Simone, Menke, Julia, Triantafyllias, Kostantinos, Vitetta, Rosetta, Russo, Alessandra, Bogliolo, Laura, Bajocchi, Gianluigi, Bravi, Elena, Barausse, Giovanni, Bortolotti, Roberto, Selmi, Carlo, Parisi, Simone, Salaffi, Fausto, Montecucco, Carlomaurizio, González-Gay, Miguel Angel, and on Behalf of AENEAS (American and European NEtwork of Antisynthetase Syndrome) Collaborative Group

Published
2017
Full Text
View/download PDF

18. Clinical Spectrum Time Course in Anti Jo-1 Positive Antisynthetase Syndrome

Author

Cavagna, Lorenzo, Nuño, Laura, Scirè, Carlo Alberto, Govoni, Marcello, Longo, Francisco Javier Lopez, Franceschini, Franco, Neri, Rossella, Castañeda, Santos, Giraldo, Walter Alberto Sifuentes, Caporali, Roberto, Iannone, Florenzo, Fusaro, Enrico, Paolazzi, Giuseppe, Pellerito, Raffaele, Schwarting, Andreas, Saketkoo, Lesley Ann, Ortego-Centeno, Norberto, Quartuccio, Luca, Bartoloni, Elena, Specker, Christof, Murcia, Trinitario Pina, La Corte, Renato, Furini, Federica, Foschi, Valentina, Corral, Javier Bachiller, Airò, Paolo, Cavazzana, Ilaria, Martínez-Barrio, Julia, Hinojosa, Michelle, Giannini, Margherita, Barsotti, Simone, Menke, Julia, Triantafyllias, Kostantinos, Vitetta, Rosetta, Russo, Alessandra, Bajocchi, Gianluigi, Bravi, Elena, Barausse, Giovanni, Bortolotti, Roberto, Selmi, Carlo, Parisi, Simone, Montecucco, Carlomaurizio, and González-Gay, Miguel Angel

Subjects
Adult, Male, Myositis, Antibodies, Antinuclear, Arthritis, Observational Study, Humans, Female, Middle Aged, Research Article, Aged, Retrospective Studies
Abstract

Anti Jo-1 antibodies are the main markers of the antisynthetase syndrome (ASSD), an autoimmune disease clinically characterized by the occurrence of arthritis, myositis, and interstitial lung disease (ILD). These manifestations usually co-occur (for practical purpose complete forms) in the same patient, but cases with only 1 or 2 of these findings (for practical purpose incomplete forms) have been described. In incomplete forms, the ex novo occurrence of further manifestations is possible, although with frequencies and timing not still defined. The aim of this international, multicenter, retrospective study was to characterize the clinical time course of anti Jo-1 positive ASSD in a large cohort of patients. Included patients should be anti Jo-1 positive and with at least 1 feature between arthritis, myositis, and ILD. We evaluated the differences between complete and incomplete forms, timing of clinical picture appearance and analyzed factors predicting the appearance of further manifestations in incomplete ASSD. Finally, we collected 225 patients (58 males and 167 females) with a median follow-up of 80 months. At the onset, complete ASSD were 44 and incomplete 181. Patients with incomplete ASSD had frequently only 1 of the classic triad findings (110 cases), in particular, isolated arthritis in 54 cases, isolated myositis in 28 cases, and isolated ILD in 28 cases. At the end of follow-up, complete ASSD were 113, incomplete 112. Only 5 patients had an isolated arthritis, only 5 an isolated myositis, and 15 an isolated ILD. During the follow-up, 108 patients with incomplete forms developed further manifestations. Single main feature onset was the main risk factor for the ex novo appearance of further manifestation. ILD was the prevalent ex novo manifestation (74 cases). In conclusion, ASSD is a condition that should be carefully considered in all patients presenting with arthritis, myositis, and ILD, even when isolated. The ex novo appearance of further manifestations in patients with incomplete forms is common, thus indicating the need for an adequate clinical and instrumental follow-up. Furthermore, the study clearly suggested that in ASSD multidisciplinary approach involving Rheumatology, Neurology, Pneumology, and Internal Medicine specialists is mandatory.

Published
2015

19. CERTAINTIES AND CONTROVERSIES OF TB DISEASE. DESCRIPTION OF TWO CLINICAL CASES

Author

Maritati, Martina, Di Nuzzo, M., Cultrera, Rosario, Vitale, P., LA CORTE, Renato, and Contini, Carlo

Subjects
MTB, other non-infectious diseases, Tuberculosis, unspecific clinical presentation, anti-TB therapy, Tuberculosis, unspecific clinical presentation, MTB, other non-infectious diseases, anti-TB therapy, NO
Published
2015

27. Dermatomiosite/polimiosite

Author

LA CORTE, Renato, Santilli, Daniele, and Trotta, Francesco

Subjects
affaticamento muscolare, muscolo, miosite, dermatomiosite, sindromi paraneoplastiche
Published
2001

35. La sindrome SAPHO

Author

Ciancio, G, Sandri, G, LA CORTE, Renato, and Trotta, Francesco

Subjects
pustolosi, spondiloartriti sieronegative, osteite-iperostosi, SAPHO
Published
1997

45. Dysfunctional inflammasome in Schnitzler's syndrome.

Author

Pizzirani, Cinzia, Falzoni, Simonetta, Govoni, Marcello, La Corte, Renato, Donadei, Simona, Di Virgilio, Francesco, Trotta, Francesco, and Monaco, Andrea Lo

Subjects
MEDICAL research, INFLAMMATION, INTERLEUKIN-1, APOPTOSIS, DRUG receptors
Abstract

Objective. IL-1β plays a key role in the pathogenesis of Schnitzler's syndrome (SS). We have investigated inflammasome activity in peripheral blood mononuclear cells (PBMCs) from a patient affected by a variant type of SS.Methods. PBMCs were purified by Ficoll and examined for ability to secrete IL-1β and -18, expression and function of the P2X7 receptor and expression of apoptosis-associated speck-like protein containing a caspase recruitment domaine (ASC) and NOD-like receptor protein 3 (NLRP3) before and after the therapy with steroid. Furthermore, extracellular adenosine 5′-triphosphate (ATP) blood levels were determined by luciferase assay. Expression of inflammasome components was measured by real time PCR and western blotting.Results. PBMCs of patient with SS showed a high, spontaneous and lipopolysaccharide-stimulated, IL-1β release but low response to stimulation with the P2X7 agonist benzoyl ATP. P2X7 expression was several fold increased, whereas ASC expression was dramatically decreased compared with PBMCs from healthy controls. NLRP3 expression was unchanged. Prednisone treatment induced remission of clinical symptoms and normalized IL-1β secretion and P2X7 and ASC expression.Conclusion. These findings reveal the presence of an overall derangement of the inflammasome and IL-1β processing and release in SS. [ABSTRACT FROM PUBLISHER]

Published
2009
Full Text
View/download PDF

46. Vascular Endothelial Growth Factor Gene Polymorphisms in Behçet's Disease

Author

Salvarani, Carlo, Boiardi, Luigi, Casali, Bruno, Olivieri, Ignazio, Cantini, Fabrizio, Salvi, Fabrizio, Malatesta, Renato, La Corte, Renato, Triolo, Giovanni, Ferrante, Angelo, Filippini, Davide, Paolazzi, Giuseppe, Sarzi-Puttini, Piercarlo, Nicoli, Davide, Farnetti, Enrico, Chen, Qingquan, and Pulsatelli, Lia

Abstract

OBJECTIVE: To evaluate potential associations of vascular endothelial growth factor (VEGF) gene polymorphisms with Behçet's disease (BD) and disease expression. METHODS: Case patients were 122 consecutive Italian patients with BD followed at the Rheumatology, Ophthalmology, and Neurology Units in Bologna, Ferrara, Milano, Palermo, Potenza, Prato, Reggio Emilia, and Trento over a 3-year period (1997-99) and who satisfied the International Study Group criteria for BD. Also selected as a control group were 200 healthy age and sex matched blood donors. All patients with BD and controls were genotyped by polymerase chain reaction and allele-specific oligonucleotide techniques for +936 C/T (rs3025039) and –634 C/G (rs2010963) mutations and for an 18 base pair (bp) insertion/deletion (I/D) polymorphism at –2549 of the the VEGF promoter region. In vitro release of VEGF by peripheral blood mononuclear cells (PBMC) was investigated by ELISA in healthy controls homozygous for the polymorphisms studied. RESULTS: The carriage rates of the alleles I and –634C were significantly more frequent in patients with BD than in healthy controls [p corr = 0.036, OR 1.8 (95% CI 1.1–2.9) and p corr = 0.05, OR 1.8 (95% CI 1.1–3.0), respectively]. While the distribution of allele +936T was similar in patients with BD and healthy controls, its frequency was significantly higher in BD patients with posterior uveitis/retinal vasculitis than in those without (p = 0.022, OR 2.4, 95% CI 1.1–5.0). Lipopolysaccharide-stimulated VEGF production from PBMC of healthy subjects was higher in II homozygous than in DD homozygous. CONCLUSION: Our data indicate that carriers of –634C and I alleles are associated with susceptibility to developing BD.

Published
2004

47. Effect of Low Dose Methotrexate on Bone Density in Women with Rheumatoid Arthritis: Results from a Multicenter Cross-Sectional Study

Author

Di Munno, Ombretta, Mazzantini, Maurizio, Sinigaglia, Luigi, Bianchi, Gerolamo, Minisola, Giovanni, Muratore, Maurizio, La Corte, Renato, Di Matteo, Luigi, Canesi, Bianca, Caminiti, Maurizio, Broggini, Marco, and Adami, Silvano

Abstract

OBJECTIVE: To analyze the influence of low dose methotrexate (MTX) on bone using data from a large multicenter, cross-sectional study on bone mineral density (BMD) in women with rheumatoid arthritis (RA). METHODS: We selected 731 female patients with RA divided into 2 groups on the basis of MTX use: never MTX users (n = 485) and MTX users for at least 6 months (n = 246). Demographic, disease, and treatment related variables were collected for each patient. BMD was measured at lumbar spine and proximal femur by dual energy x-ray absorptiometry. Osteoporosis was defined as BMD < –2.5 T-score. RESULTS: The frequency of osteoporosis among never MTX users and MTX users was 29.1% and 28.3% (p = NS) for lumbar spine, and 34.8% and 37.8% (p = NS) for femoral neck, respectively. Mean T-score values at lumbar spine and femoral neck were comparable in the 2 groups, even after adjusting for age, menopausal status, body mass index (BMI), Health Assessment Questionnaire (HAQ) score, and steroid use. The generalized linear model showed that age, menopause, BMI, HAQ score, and steroid use were significant independent predictors of BMD at lumbar or at femoral level, whereas MTX use was not. Logistic procedure showed that only age, HAQ score, and BMI were significantly associated with the risk of osteoporosis. CONCLUSION: We found no negative effect of low dose MTX on BMD in women with RA.

Published
2004

49. POLIENTESOPATIA IPEROSTOSANTE DISMETABOLICA

Author

Pellegrini, Pietro, Bazzanini, G, Cervi, G, DELLI GATTI, I, Dovigo, Livio, Govoni, Marcello, LA CORTE, Renato, Menegale, G, Scaramelli, M, and Trotta, Francesco

Published
1986

Catalog

Books, media, physical & digital resources
See catalog results